个人中心 - 老虎社区

19d7ed83

IP属地：未知

帖子 · 24帖子 · 24
关注 · 0关注 · 0
粉丝 · 0粉丝 · 0

- 19d7ed8319d7ed83
  ·2021-06-18
  Shell out more money
  非常抱歉，此主贴已删除
  2,019 评论
  3
  分享
  举报
- 19d7ed8319d7ed83
  ·2021-06-18
  Uh oh, maybe business will fold soon
  非常抱歉，此主贴已删除
  980 评论
  1
  分享
  举报
- 19d7ed8319d7ed83
  ·2021-06-18
  Uh oh orphazyme
  1,207 评论
  点赞
  分享
  举报
- 19d7ed8319d7ed83
  ·2021-06-18
  Ok here we go
  非常抱歉，此主贴已删除
  2,517 评论
  点赞
  分享
  举报
- 19d7ed8319d7ed83
  ·2021-06-18
  Wow who would've guessed
  非常抱歉，此主贴已删除
  676 评论
  1
  分享
  举报
- 19d7ed8319d7ed83
  ·2021-06-18
  This is so sad
  Orphazyme shares tumbled more than 60% in pre-market trading
  Orphazyme shares tumbled more than 60% in pre-market trading. Orphazyme slashed its financial foreca
  Orphazyme shares tumbled more than 60% in pre-market trading
  1,066 1
  2
  分享
  举报
- 19d7ed8319d7ed83
  ·2021-06-18
  Ford looks good to buy
  非常抱歉，此主贴已删除
  1,559 1
  7
  分享
  举报
- 19d7ed8319d7ed83
  ·2021-06-18
  They will always win
  非常抱歉，此主贴已删除
  999 评论
  点赞
  分享
  举报
- 19d7ed8319d7ed83
  ·2021-06-18
  Post here
  1,037 评论
  点赞
  分享
  举报
- 19d7ed8319d7ed83
  ·2021-06-18
  Apple try harder
  Apple Struggles in Push to Make Healthcare Its Greatest Legacy
  Tech giant has envisioned hiring doctors to offer primary care, now focused on Watch Under the leade
  Apple Struggles in Push to Make Healthcare Its Greatest Legacy
  1,136 评论
  点赞
  分享
  举报
暂无关注

热议股票

{"i18n":{"language":"zh_CN"},"isCurrentUser":false,"userPageInfo":{"id":"3582871469502818","uuid":"3582871469502818","gmtCreate":1619778373061,"gmtModify":1619778373061,"name":"19d7ed83","pinyin":"bcwy","introduction":"","introductionEn":"","signature":"","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":1,"headSize":0,"tweetSize":24,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.09.16","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":2,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":1,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":166644647,"gmtCreate":1624008474089,"gmtModify":1631892560309,"author":{"id":"3582871469502818","authorId":"3582871469502818","name":"19d7ed83","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582871469502818","idStr":"3582871469502818"},"themes":[],"htmlText":"Shell out more money","listText":"Shell out more money","text":"Shell out more money","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/166644647","repostId":"1181667218","repostType":4,"isVote":1,"tweetType":1,"viewCount":2019,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":166642240,"gmtCreate":1624008407380,"gmtModify":1631892560323,"author":{"id":"3582871469502818","authorId":"3582871469502818","name":"19d7ed83","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582871469502818","idStr":"3582871469502818"},"themes":[],"htmlText":"Uh oh, maybe business will fold soon","listText":"Uh oh, maybe business will fold soon","text":"Uh oh, maybe business will fold soon","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/166642240","repostId":"1176081814","repostType":4,"isVote":1,"tweetType":1,"viewCount":980,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":166646213,"gmtCreate":1624008372332,"gmtModify":1631892560334,"author":{"id":"3582871469502818","authorId":"3582871469502818","name":"19d7ed83","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582871469502818","idStr":"3582871469502818"},"themes":[],"htmlText":"Uh oh orphazyme","listText":"Uh oh orphazyme","text":"Uh oh orphazyme","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/166646213","isVote":1,"tweetType":1,"viewCount":1207,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":166648869,"gmtCreate":1624008279651,"gmtModify":1631892560348,"author":{"id":"3582871469502818","authorId":"3582871469502818","name":"19d7ed83","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582871469502818","idStr":"3582871469502818"},"themes":[],"htmlText":"Ok here we go","listText":"Ok here we go","text":"Ok here we go","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/166648869","repostId":"2143926717","repostType":2,"isVote":1,"tweetType":1,"viewCount":2517,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":166648341,"gmtCreate":1624008259483,"gmtModify":1631892560359,"author":{"id":"3582871469502818","authorId":"3582871469502818","name":"19d7ed83","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582871469502818","idStr":"3582871469502818"},"themes":[],"htmlText":"Wow who would've guessed","listText":"Wow who would've guessed","text":"Wow who would've guessed","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/166648341","repostId":"1113093847","repostType":4,"isVote":1,"tweetType":1,"viewCount":676,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":166641587,"gmtCreate":1624008226649,"gmtModify":1631892560380,"author":{"id":"3582871469502818","authorId":"3582871469502818","name":"19d7ed83","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582871469502818","idStr":"3582871469502818"},"themes":[],"htmlText":"This is so sad","listText":"This is so sad","text":"This is so sad","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/166641587","repostId":"1142916683","repostType":4,"repost":{"id":"1142916683","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1624003342,"share":"https://www.laohu8.com/m/news/1142916683?lang=&edition=full","pubTime":"2021-06-18 16:02","market":"us","language":"en","title":"Orphazyme shares tumbled more than 60% in pre-market trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1142916683","media":"Tiger Newspress","summary":"Orphazyme shares tumbled more than 60% in pre-market trading.\nOrphazyme slashed its financial foreca","content":"<p>Orphazyme&nbsp;shares&nbsp;tumbled&nbsp;more&nbsp;than&nbsp;60% in pre-market&nbsp;trading.</p>\n<p><img src=\"https://static.tigerbbs.com/b722b82c7d6ab2a6fcc7364eb2517b7f\" tg-width=\"1293\" tg-height=\"628\" referrerpolicy=\"no-referrer\">Orphazyme slashed its financial forecasts on Friday after U.S. health regulators rejected its key drug candidate.</p>\n<p>Orphazyme said its application for FDA approval of arimoclomol, a treatment for genetic disorder Niemann-Pick disease type C, had not been successful.</p>\n<p>As a result, it predicted revenue for the year would be lower than previously expected and its operating loss significantly wider, forcing the company to cut costs.</p>\n<p>\"Orphazyme has no money and no substantial projects ... Investors have put their money into a completely unrealistic scenario driven by 'meme tendencies',\" broker Nordnet wrote in a note to clients.</p>\n<p>Orphazyme, which is listed in Copenhagen and New York, now expects an operating loss of 670-700 million crowns ($107-$112 million) in 2021, against a previous forecast for a loss of 100-150 million crowns.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Orphazyme shares tumbled more than 60% in pre-market trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOrphazyme shares tumbled more than 60% in pre-market trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-06-18 16:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Orphazyme&nbsp;shares&nbsp;tumbled&nbsp;more&nbsp;than&nbsp;60% in pre-market&nbsp;trading.</p>\n<p><img src=\"https://static.tigerbbs.com/b722b82c7d6ab2a6fcc7364eb2517b7f\" tg-width=\"1293\" tg-height=\"628\" referrerpolicy=\"no-referrer\">Orphazyme slashed its financial forecasts on Friday after U.S. health regulators rejected its key drug candidate.</p>\n<p>Orphazyme said its application for FDA approval of arimoclomol, a treatment for genetic disorder Niemann-Pick disease type C, had not been successful.</p>\n<p>As a result, it predicted revenue for the year would be lower than previously expected and its operating loss significantly wider, forcing the company to cut costs.</p>\n<p>\"Orphazyme has no money and no substantial projects ... Investors have put their money into a completely unrealistic scenario driven by 'meme tendencies',\" broker Nordnet wrote in a note to clients.</p>\n<p>Orphazyme, which is listed in Copenhagen and New York, now expects an operating loss of 670-700 million crowns ($107-$112 million) in 2021, against a previous forecast for a loss of 100-150 million crowns.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1142916683","content_text":"Orphazyme shares tumbled more than 60% in pre-market trading.\nOrphazyme slashed its financial forecasts on Friday after U.S. health regulators rejected its key drug candidate.\nOrphazyme said its application for FDA approval of arimoclomol, a treatment for genetic disorder Niemann-Pick disease type C, had not been successful.\nAs a result, it predicted revenue for the year would be lower than previously expected and its operating loss significantly wider, forcing the company to cut costs.\n\"Orphazyme has no money and no substantial projects ... Investors have put their money into a completely unrealistic scenario driven by 'meme tendencies',\" broker Nordnet wrote in a note to clients.\nOrphazyme, which is listed in Copenhagen and New York, now expects an operating loss of 670-700 million crowns ($107-$112 million) in 2021, against a previous forecast for a loss of 100-150 million crowns.","news_type":1,"symbols_score_info":{"ORPH":0.9}},"isVote":1,"tweetType":1,"viewCount":1066,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":166641861,"gmtCreate":1624008197353,"gmtModify":1631884994019,"author":{"id":"3582871469502818","authorId":"3582871469502818","name":"19d7ed83","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582871469502818","idStr":"3582871469502818"},"themes":[],"htmlText":"Ford looks good to buy&nbsp;","listText":"Ford looks good to buy&nbsp;","text":"Ford looks good to buy","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/166641861","repostId":"2144172072","repostType":4,"isVote":1,"tweetType":1,"viewCount":1559,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":166641940,"gmtCreate":1624008161080,"gmtModify":1631892560388,"author":{"id":"3582871469502818","authorId":"3582871469502818","name":"19d7ed83","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582871469502818","idStr":"3582871469502818"},"themes":[],"htmlText":"They will always win","listText":"They will always win","text":"They will always win","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/166641940","repostId":"2144861727","repostType":2,"isVote":1,"tweetType":1,"viewCount":999,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":168358986,"gmtCreate":1623953223445,"gmtModify":1631884647186,"author":{"id":"3582871469502818","authorId":"3582871469502818","name":"19d7ed83","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582871469502818","idStr":"3582871469502818"},"themes":[],"htmlText":"Post here","listText":"Post here","text":"Post here","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/168358986","isVote":1,"tweetType":1,"viewCount":1037,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":168351480,"gmtCreate":1623953188340,"gmtModify":1631892560401,"author":{"id":"3582871469502818","authorId":"3582871469502818","name":"19d7ed83","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582871469502818","idStr":"3582871469502818"},"themes":[],"htmlText":"Apple try harder","listText":"Apple try harder","text":"Apple try harder","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/168351480","repostId":"1139981231","repostType":2,"repost":{"id":"1139981231","kind":"news","pubTimestamp":1623910261,"share":"https://www.laohu8.com/m/news/1139981231?lang=&edition=full","pubTime":"2021-06-17 14:11","market":"us","language":"en","title":"Apple Struggles in Push to Make Healthcare Its Greatest Legacy","url":"https://stock-news.laohu8.com/highlight/detail?id=1139981231","media":"The Wall Street Journal","summary":"Tech giant has envisioned hiring doctors to offer primary care, now focused on Watch\nUnder the leade","content":"<p>Tech giant has envisioned hiring doctors to offer primary care, now focused on Watch</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/cdcc89ff3fd1e1d8ec3f02f3aaf52457\" tg-width=\"1260\" tg-height=\"840\" referrerpolicy=\"no-referrer\"><span>Under the leadership of CEO Tim Cook, Apple has increased its research-and-development budget eightfold to $20 billion annually.</span></p>\n<p>Apple&nbsp;Inc.&nbsp;Chief Executive Tim Cook has said the company’s greatest contribution to mankind will be in health. So far, some Apple initiatives aimed at broadly disrupting the healthcare sector have struggled to gain traction, according to people familiar with them and documents reviewed by The Wall Street Journal.</p>\n<p>Apple has envisioned an audacious plan for healthcare, offering its own primary-care medical service with Apple-employed doctors at its own clinics, according to people familiar with the plan and documents. To test that and other bold healthcare ideas, it took over clinics that catered to its employees and built a team with scores of clinicians, engineers, product designers and others.</p>\n<p>Today those ambitions, which aren’t widely known, have largely stalled as Apple has shifted the focus of its health unit to something it knows well: Selling devices, specifically the Apple Watch, according to people familiar with its strategy.</p>\n<p>The new primary-care service hasn’t gotten off the ground, people familiar with it say. A digital health app launched quietly this year has struggled to keep users engaged, say people familiar with the app and the documents seen by the Journal. Some employees have raised questions internally about the integrity of health data coming from the company’s clinics that has been used to support product development, according to people familiar with their concerns and the documents.</p>\n<p>An Apple spokesman said data integrity is the foundation for all of the company’s innovations. He pointed to the accomplishments of its health team and said the company is still in the early innings of its work in healthcare, adding that new technology such as&nbsp;heart-rate notifications&nbsp;in products like the Apple Watch have improved users’ health. He said data gathered by Apple’s devices is enabling new research that has the potential to improve care.</p>\n<p>“Many of the assertions in this report are based on incomplete, outdated and inaccurate information,” the spokesman said.</p>\n<p>Looking for new markets where technology can improve efficiency and outcomes—and power sales growth—the tech sector has eyed healthcare as an untapped opportunity. Some of tech’s biggest efforts have failed, includingHaven,Amazon.com&nbsp;Inc.’s&nbsp;high-profile partnership with other companies that aimed to reduce healthcare costs. Today, Amazon has a new effort to sell prescriptions and a plan to launch&nbsp;virtual care across 50 states.</p>\n<p>Under Mr. Cook’s leadership, Apple has increased its research-and-development budget eightfold to $20 billion annually, according to its public filings. And besides a smartwatch, the company has released wireless headphones as well as new services. It has also invested heavily in health, autonomous driving and augmented reality, all technically complex, high-stakes areas, meaning that game-changing offerings could be years away or never come.</p>\n<p>Apple can study markets for years before coming up with its own offering, and it sometimes works extensively on new projects or technologies that it ultimately doesn’t bring to market.</p>\n<p>One of its most ambitious healthcare ideas was a plan to offer primary-care medicine, conceived in 2016, according to documents and the people familiar with the plan. An Apple team spent months trying to figure out how the flood of health and wellness data collected from users of its smartwatch, first released in 2015, might be used to improve healthcare, the people said.</p>\n<p>Apple Chief Operating Officer Jeff Williams, who oversees the health team, urged employees to think big. He said Apple should disrupt what he called the “363” and “break fix” model of care in the U.S., where patients may not see their doctors 363 days a year and only visit when something goes wrong, according to people familiar with his ideas.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/837161c8fc0a7b93c5c67936fe293453\" tg-width=\"1260\" tg-height=\"840\"><span>Apple Chief Operating Officer Jeff Williams oversees its health unit.</span></p>\n<p>The team decided one of the best ways to realize that vision was to provide a medical service of its own, said people familiar with the plan, linking data generated by Apple devices with virtual and in-person care provided by Apple doctors. Apple would offer primary care, but also continuous health monitoring as part of a subscription-based personalized health program, according to these people and the documents.</p>\n<p>If Apple could prove that its combination of device sensors, software and services could improve people’s health and lower costs, the company could franchise the model to health systems and even other countries, according to the documents.</p>\n<p>To start, Apple chose to test the service out on its own employees. Apple took over employee health clinics near its headquarters that were being run by a startup and turned them into test beds for new health services, say people familiar with the changes. In 2017 it hired Dr. Sumbul Desai from Stanford University to run the effort, which was given the code name Casper, said the people familiar with the plan.</p>\n<p>The effort continues today, but Apple has struggled to move Casper past a preliminary stage, say people familiar with its operations.</p>\n<p>Dr. Desai’s unit in particular has seen multiple departures by employees who say its culture discourages critical feedback, which is potentially problematic for a unit focused on products and services related to personal health, according to people familiar with its culture and the documents. Some employees expressed concerns that internal data about the clinics’ performance, data that was recently used to support the rollout of a new digital health app, has been inaccurate or compiled haphazardly, according to the documents and people familiar with the data.</p>\n<p>Those issues have been repeatedly voiced to Messrs. Cook and Williams, according to the documents and people familiar with the issues.</p>\n<p>Apple’s spokesman said such criticisms are inaccurate.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/01a35a283d15f6de16455cae846a617b\" tg-width=\"1260\" tg-height=\"840\"><span>Dr. Sumbul Desai runs a team that oversees clinics, handles relations with regulators and spearheads research collaborations.</span></p>\n<p>Employees concerned about the culture pointed to a 2019 meeting during which a midlevel manager raised questions about data, according to people familiar with the meeting and the documents. Dr. Desai responded angrily, leading some present to conclude that critical questions were unwelcome, according to the people and the documents. The manager left Apple weeks later and the episode contributed to her departure, documents show.</p>\n<p>Apple’s spokesman said Dr. Desai spoke to the importance of data integrity in the meeting. “This matter was investigated thoroughly and the allegations could not be substantiated,” the spokesman said. Apple declined to comment on the circumstances of the employee’s departure.</p>\n<p>The spokesman said the company is proud of Dr. Desai’s work and that she has been instrumental in much of its healthcare work.</p>\n<p>Mr. Williams and Dr. Desai didn’t respond to a request for comment and Apple declined to make them available.</p>\n<p>In addition to overseeing the clinics, known as AC Wellness, Dr. Desai’s team handles relations with regulators, spearheads research collaborations and provides clinical expertise on other health products at Apple.</p>\n<p>A recent initiative for Dr. Desai’s team, a digital health app called HealthHabit that is being tested on California-based Apple employees, has struggled with low engagement since the app’s launch roughly six months ago, according to documents and people familiar with the app.</p>\n<p>HealthHabit&nbsp;offers to connect people with clinicians via chat and encourages them to set health challenges such as “I will exercise more this week.” Those with a history of hypertension can be connected to health coaches who can send them a blood-pressure monitor and scale and advise them on healthier habits.</p>\n<p>Half the people who had downloaded it as of May hadn’t enrolled and engagement among many who have enrolled has been low, according to the documents and people familiar with the app.</p>\n<p>Data supporting the app’s hypertension program has caused new concerns among employees about the integrity of internal data and analysis, some of the people said.</p>\n<p>During a presentation for all Apple health employees in March, Mr. Williams praised the clinics’ results in treating hypertension and pointed to them as evidence supporting the HealthHabit app’s potential, according to people who saw the presentation. He suggested that the company may have wider ambitions for the app if it is successful, they said.</p>\n<p>In the meeting, Mr. Williams showed data indicating that 91% of patients in Apple’s clinics with more severe stage-two hypertension improved to healthier stages or normal, according to documents reviewed by the Journal, a figure that some employees feared could overstate the clinics’ success, according to people who attended the meeting and documents.</p>\n<p>Rival companies offering hypertension apps have disclosed lower rates of success. Hello Heart Inc. reported 23% of stage 2 patients saw a significant improvement in blood pressure at 6 weeks. Livongo claimed one-third of patients with stage one hypertension or worse improved to an elevated or normal range in 6 weeks. Mr. Williams’s data didn’t include a time frame, according to the documents.</p>\n<p>The Apple spokesman said that other companies analyze their hypertension data differently and that the data cited by Mr. Williams in the meeting was for an internal pilot, not a product.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Apple Struggles in Push to Make Healthcare Its Greatest Legacy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nApple Struggles in Push to Make Healthcare Its Greatest Legacy\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-17 14:11 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.wsj.com/articles/apple-struggles-in-push-to-make-healthcare-greatest-legacy-11623832200?mod=hp_lead_pos3><strong>The Wall Street Journal</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Tech giant has envisioned hiring doctors to offer primary care, now focused on Watch\nUnder the leadership of CEO Tim Cook, Apple has increased its research-and-development budget eightfold to $20 ...</p>\n\n<a href=\"https://www.wsj.com/articles/apple-struggles-in-push-to-make-healthcare-greatest-legacy-11623832200?mod=hp_lead_pos3\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AAPL":"苹果"},"source_url":"https://www.wsj.com/articles/apple-struggles-in-push-to-make-healthcare-greatest-legacy-11623832200?mod=hp_lead_pos3","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1139981231","content_text":"Tech giant has envisioned hiring doctors to offer primary care, now focused on Watch\nUnder the leadership of CEO Tim Cook, Apple has increased its research-and-development budget eightfold to $20 billion annually.\nApple Inc. Chief Executive Tim Cook has said the company’s greatest contribution to mankind will be in health. So far, some Apple initiatives aimed at broadly disrupting the healthcare sector have struggled to gain traction, according to people familiar with them and documents reviewed by The Wall Street Journal.\nApple has envisioned an audacious plan for healthcare, offering its own primary-care medical service with Apple-employed doctors at its own clinics, according to people familiar with the plan and documents. To test that and other bold healthcare ideas, it took over clinics that catered to its employees and built a team with scores of clinicians, engineers, product designers and others.\nToday those ambitions, which aren’t widely known, have largely stalled as Apple has shifted the focus of its health unit to something it knows well: Selling devices, specifically the Apple Watch, according to people familiar with its strategy.\nThe new primary-care service hasn’t gotten off the ground, people familiar with it say. A digital health app launched quietly this year has struggled to keep users engaged, say people familiar with the app and the documents seen by the Journal. Some employees have raised questions internally about the integrity of health data coming from the company’s clinics that has been used to support product development, according to people familiar with their concerns and the documents.\nAn Apple spokesman said data integrity is the foundation for all of the company’s innovations. He pointed to the accomplishments of its health team and said the company is still in the early innings of its work in healthcare, adding that new technology such as heart-rate notifications in products like the Apple Watch have improved users’ health. He said data gathered by Apple’s devices is enabling new research that has the potential to improve care.\n“Many of the assertions in this report are based on incomplete, outdated and inaccurate information,” the spokesman said.\nLooking for new markets where technology can improve efficiency and outcomes—and power sales growth—the tech sector has eyed healthcare as an untapped opportunity. Some of tech’s biggest efforts have failed, includingHaven,Amazon.com Inc.’s high-profile partnership with other companies that aimed to reduce healthcare costs. Today, Amazon has a new effort to sell prescriptions and a plan to launch virtual care across 50 states.\nUnder Mr. Cook’s leadership, Apple has increased its research-and-development budget eightfold to $20 billion annually, according to its public filings. And besides a smartwatch, the company has released wireless headphones as well as new services. It has also invested heavily in health, autonomous driving and augmented reality, all technically complex, high-stakes areas, meaning that game-changing offerings could be years away or never come.\nApple can study markets for years before coming up with its own offering, and it sometimes works extensively on new projects or technologies that it ultimately doesn’t bring to market.\nOne of its most ambitious healthcare ideas was a plan to offer primary-care medicine, conceived in 2016, according to documents and the people familiar with the plan. An Apple team spent months trying to figure out how the flood of health and wellness data collected from users of its smartwatch, first released in 2015, might be used to improve healthcare, the people said.\nApple Chief Operating Officer Jeff Williams, who oversees the health team, urged employees to think big. He said Apple should disrupt what he called the “363” and “break fix” model of care in the U.S., where patients may not see their doctors 363 days a year and only visit when something goes wrong, according to people familiar with his ideas.\nApple Chief Operating Officer Jeff Williams oversees its health unit.\nThe team decided one of the best ways to realize that vision was to provide a medical service of its own, said people familiar with the plan, linking data generated by Apple devices with virtual and in-person care provided by Apple doctors. Apple would offer primary care, but also continuous health monitoring as part of a subscription-based personalized health program, according to these people and the documents.\nIf Apple could prove that its combination of device sensors, software and services could improve people’s health and lower costs, the company could franchise the model to health systems and even other countries, according to the documents.\nTo start, Apple chose to test the service out on its own employees. Apple took over employee health clinics near its headquarters that were being run by a startup and turned them into test beds for new health services, say people familiar with the changes. In 2017 it hired Dr. Sumbul Desai from Stanford University to run the effort, which was given the code name Casper, said the people familiar with the plan.\nThe effort continues today, but Apple has struggled to move Casper past a preliminary stage, say people familiar with its operations.\nDr. Desai’s unit in particular has seen multiple departures by employees who say its culture discourages critical feedback, which is potentially problematic for a unit focused on products and services related to personal health, according to people familiar with its culture and the documents. Some employees expressed concerns that internal data about the clinics’ performance, data that was recently used to support the rollout of a new digital health app, has been inaccurate or compiled haphazardly, according to the documents and people familiar with the data.\nThose issues have been repeatedly voiced to Messrs. Cook and Williams, according to the documents and people familiar with the issues.\nApple’s spokesman said such criticisms are inaccurate.\nDr. Sumbul Desai runs a team that oversees clinics, handles relations with regulators and spearheads research collaborations.\nEmployees concerned about the culture pointed to a 2019 meeting during which a midlevel manager raised questions about data, according to people familiar with the meeting and the documents. Dr. Desai responded angrily, leading some present to conclude that critical questions were unwelcome, according to the people and the documents. The manager left Apple weeks later and the episode contributed to her departure, documents show.\nApple’s spokesman said Dr. Desai spoke to the importance of data integrity in the meeting. “This matter was investigated thoroughly and the allegations could not be substantiated,” the spokesman said. Apple declined to comment on the circumstances of the employee’s departure.\nThe spokesman said the company is proud of Dr. Desai’s work and that she has been instrumental in much of its healthcare work.\nMr. Williams and Dr. Desai didn’t respond to a request for comment and Apple declined to make them available.\nIn addition to overseeing the clinics, known as AC Wellness, Dr. Desai’s team handles relations with regulators, spearheads research collaborations and provides clinical expertise on other health products at Apple.\nA recent initiative for Dr. Desai’s team, a digital health app called HealthHabit that is being tested on California-based Apple employees, has struggled with low engagement since the app’s launch roughly six months ago, according to documents and people familiar with the app.\nHealthHabit offers to connect people with clinicians via chat and encourages them to set health challenges such as “I will exercise more this week.” Those with a history of hypertension can be connected to health coaches who can send them a blood-pressure monitor and scale and advise them on healthier habits.\nHalf the people who had downloaded it as of May hadn’t enrolled and engagement among many who have enrolled has been low, according to the documents and people familiar with the app.\nData supporting the app’s hypertension program has caused new concerns among employees about the integrity of internal data and analysis, some of the people said.\nDuring a presentation for all Apple health employees in March, Mr. Williams praised the clinics’ results in treating hypertension and pointed to them as evidence supporting the HealthHabit app’s potential, according to people who saw the presentation. He suggested that the company may have wider ambitions for the app if it is successful, they said.\nIn the meeting, Mr. Williams showed data indicating that 91% of patients in Apple’s clinics with more severe stage-two hypertension improved to healthier stages or normal, according to documents reviewed by the Journal, a figure that some employees feared could overstate the clinics’ success, according to people who attended the meeting and documents.\nRival companies offering hypertension apps have disclosed lower rates of success. Hello Heart Inc. reported 23% of stage 2 patients saw a significant improvement in blood pressure at 6 weeks. Livongo claimed one-third of patients with stage one hypertension or worse improved to an elevated or normal range in 6 weeks. Mr. Williams’s data didn’t include a time frame, according to the documents.\nThe Apple spokesman said that other companies analyze their hypertension data differently and that the data cited by Mr. Williams in the meeting was for an internal pilot, not a product.","news_type":1,"symbols_score_info":{"AAPL":0.9}},"isVote":1,"tweetType":1,"viewCount":1136,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"defaultTab":"following","isTTM":false}